Cliniques Universitaires Saint-Luc
8
3
3
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
12.5%
1 terminated/withdrawn out of 8 trials
25%
2 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
Role: lead
Study of clinical response, MRI progression, synovitis and changes in gene expression profiles in response to Sarilumab in patients with rheumatoid arthritis not responding to ANTI-TNF therapy
Role: lead
Study on the detection of cardiac inflammation by PET-CT imaging with a new tracer called '68Ga-NOTA-Anti-MMR-VHH2' in patients with cardiac sarcoidosis.
Role: lead
Monocentric Pilot Trial evaluating the safety and efficacy of Regorafenib in Arterio-Venous Malformations that are refractory to standard care
Role: lead
Multicentric study evaluating the usefulness of early PSMA PET scan in metastatic renal cancer requiring standard immunotherapy treatment.
Role: lead
Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms.
Role: lead
Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy
Role: lead
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-label, controlled, randomized multinational pragmatic trial.
Role: lead
All 8 trials loaded